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ABSTRACT 
Objective: The main objective of the present investigation is to develop a sustained-release (SR) formulation to optimize the postprandial elevation 
of glucose level in type 2 Diabetic subjects using combination therapy. In the present research work, bilayer sustained release formulation of 
metformin hydrochloride (MFH) and gliclazide (GLZ), based on monolithic-matrix technology was developed and evaluated.  
Methods: The formulations of metformin hydrochloride layer and gliclazide layer that contain polyox WSR coagulant and different viscosity grades 
of hydroxyl propyl methylcellulose (HPMC) as sustained-release matrix were prepared by direct compression and wet granulation method 
respectively. The bilayer tablets were prepared after carrying out the optimization of metformin layer and evaluated for various pre-compression 
and post-compression parameters. For the best formulation selected on basis of in vitro evaluation of tablets, Fourier-transform infrared 
spectroscopy (FT-IR) studies and comparison of in vitro dissolution profile of developed formulation with the innovator were performed.  
Results: Metformin hydrochloride and gliclazide showed sustained release of drug by diffusion mechanism and followed first-order kinetics. The 
best formulation of metformin hydrochloride (M7) and gliclazide (G8) show 99.93% and 99.65% of drug release in 24 h respectively. The similarity 
factor (f2) was 79.95 for metformin hydrochloride and 73.62 for gliclazide when compared with the innovator.  
Conclusion: The monolith diffusion-controlled bilayer tablets of metformin hydrochloride and gliclazide offer improved patient compliance and 
convenience with better postprandial hyperglycemic control with once-a-day dosing. The sustained release of the drug up to 24 h regulate 
antidiabetic activity round the clock with minimal side effects. 
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INTRODUCTION 
Insulin is an anabolic hormone responsible for the maintenance of 
glucose homeostasis in the human body. It helps in the uptake of 
glucose molecules into the tissues and results in the utilization of 
glucose moiety into energy by various biochemical mechanisms [1]. 
However, lack of adequate insulin levels in our body leads to several 
chronic metabolic disturbances of carbohydrate, fat, and protein that 
is often termed as diabetes mellitus (DM) which is a serious and 
lifelong condition [2]. There are two principal forms of diabetes: type 1 
diabetes, in which the pancreas fails to produce insulin, and type 2 
diabetes, which results from the body’s inability to respond properly 
to the action of insulin produced by the pancreas [3]. The prevalence 
of diabetes has increased globally over the years and it has been noted 
as one of the leading causes of high mortality and morbidity rate [4]. 
About 422 million people worldwide have diabetes and 1.6 million 
deaths are directly attributed to diabetes each year [5]. According to 
the IDF statistics, adults with type 2 diabetes (T2 DM) outnumber 
those with type 1 diabetes [6]. Type 2 DM is a heterogeneous disorder 
characterized by multiple problems in the pancreatic β-cell, liver, and 
peripheral tissue such as skeletal muscles and adipose tissue. These 
multiple complications are well managed by combination therapy 
using two antidiabetic drugs. Combination therapy is more 
advantageous than monotherapy in minimizing problems such as 
dose-dependent side effects, dosing frequency, etc. A low-dose 
combination of two different drugs reduces dose-related risks and 
minimizes the clinical and metabolic side effects that occur with the 
maximal dosage of individual components as in monotherapy, and 
thus dosage of the single components can be reduced [7, 8]. Diabetes 
needs much attention as glucose levels that tend to increase after a 
meal, have to maintain for the whole day for proper activity of the 
body [9]. To combat such conditions, sustained-release (SR) 
formulations that regulate antidiabetic activity round the clock need to 
develop to optimize the postprandial elevation of glucose levels [10]. 
Metformin hydrochloride, an oral biguanide first-line choice of drug 
and gliclazide (GLZ), the second-generation sulphonylurea provides 
good hypoglycemic excellence by increasing both basal and meal-
stimulated insulin secretion along with enhancement of peripheral 
insulin sensitivity, ultimately leading to declining in fasting, 
postprandial glucose, and glycosylated hemoglobin (HbA1c) levels 
[11]. Bilayer technology is one of the suitable approaches for the 
successful development of sustained-release formulations that provide 
a way of successful drug delivery. A bi-layer tablet is suitable for the 
fabrication of sustained release dosage form (tablet) consisting of two 
drugs in combination in two different layers and sequentially release the 
drugs [12]. The present research aimed to develop a sustained release 
bilayer formulation using combination therapy, which provides better 
postprandial hyperglycemic control with a daylong duration and reduces 
the economic burden in management of diabetes compared to the 
expenses in marketing new drug entities. The objective of the present 
investigation is to design and evaluate sustained release bilayer tablets 
containing metformin hydrochloride and gliclazide. 
MATERIALS AND METHODS 
Materials 
Metformin hydrochloride and gliclazide were supplied as a gift 
sample from Cipla Pharmaceuticals Ltd., Mumbai. Desai chemicals 
Ltd remained as a main supplier for the polyox WSR coagulant, 
HPMC polymers of grade K4M, K15M, K100M and all other 
excipients used in the study. HPLC grade acetonitrile, potassium 
dihydrogen phosphate, orthophosphoric acid AR grade purchased 
from Lotus Chem. Mumbai, India. Waters e 2695 separation module 
with high pressure liquid chromatographic instrument provided 
with an RP-Select B C18 column (250 mm x 4.6 mm; 5µ) and 2489 
UV-Visible detector, auto-injector, an autosampler with Empower 2 
software from Waters Corporation, Milford USA was employed in 
the study. 
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Drug-excipient interaction study 
It is a critical primary concern for any dosage form to study the 
compatibility of drug, polymer and other excipients; therefore, it is 
necessary to confirm that the drug does not interact with polymers 
and excipients under experimental conditions and affects the shelf 
life of the product. The drug excipient compatibility has done by 
physical observation of mixtures for one month and FT-IR study. The 
drug has mixed with excipients in a different ratio. These mixtures 
were kept in 5 ml glass white-colored vials and packed properly. 
These vials were exposed to room temperature and 40˚C/75 % RH. 2 
to 3 g of the blend was prepared and filled in three vials. 
Observations for any physical change in appearance were performed 
at zero weeks to one month [13]. 
FTIR spectroscopy 
Fourier transform infrared spectroscopy (FT-IR) investigations were 
used to detect possible drug-drug and drug-excipient interactions by 
using an FT-IR spectrometer–430 (Jasco-Japan). The Potassium 
Bromide pellets, an infrared transparent matrix, were prepared on 
KBr press on grounding the solid powder sample with 100 times the 
quantity of KBr in a mortar [14]. The spectra were recorded at a 
resolution of 4 cm-1 over the wavenumber of 4000 to 400/cm.  
Analytical method 
Preparation of stock and working standard solution of 
metformin hydrochloride and gliclazide 
A mixture of pH 6.6 phosphate buffer and acetonitrile in the ratio 
60:40 % v/v filtered through 0.45µ membrane filter used as mobile 
phase for preparing the working solution of the drug. About 500 mg of 
metformin hydrochloride and 60 mg of gliclazide were accurately 
weighed and transferred into a 100 ml volumetric flask, the solution 
was sonicated and the resulting solution was diluted with the mobile 
phase to obtain a primary stock solution. 10 ml of this stock solution 
was further diluted to 100 ml using mobile phase to obtain 500 µg/ml 
metformin hydrochloride and 60 µg/ml gliclazide. From this solution, 
suitable working solutions of different concentrations were prepared. 
Construction of calibration curve of metformin hydrochloride 
and gliclazide 
Linearity of the peak area response was determined by measuring 
working standard dilution of metformin hydrochloride and gliclazide 
in the range of 125-750 µg/ml and 20-120 µg/ml respectively. 
Triplicate of the 20-µl quantity of each dilution injected each time into 
the column. The drug in elutes was monitored at 261 nm and the 
corresponding chromatograms were obtained. From these 
chromatograms, a plot of amount and response was constructed. The 
regression equation (fig. 1 and 2) obtained was used to estimate the 
amount of drugs present in a pharmaceutical dosage form. 
 
 
Fig. 1: Calibration curve of metformin hydrochloride 
 
 
Fig. 2: Calibration curve of gliclazide 
 
Formulation development of bilayer tablets  
Development of bilayer tablets of metformin hydrochloride and 
gliclazide was carried out in two stages. Blends of the SR layer of 
metformin hydrochloride (layer 1) and gliclazide (layer 2) were 
prepared and initially compressed separately for preliminary 
evaluations. After optimization of an individual layer, the bilayer 
tablet was prepared using selected formulas. 
Formulation of metformin hydrochloride layer (layer-1) 
Metformin hydrochloride is a very moisture-sensitive drug. Hence, 
various formulations of metformin hydrochloride were prepared by 
non-aqueous wet granulation (M1-M4) and direct compression (M5-
M7). In formulations, (M1-M4) HPMC K100M was used as a 
retardant. All the ingredients passed through a 60-mesh sieve. A 
blend of all ingredients was mixed thoroughly in a rapid mixer 
granulator resulting in phase homogenization and granulated 
manually with a binder solution, which was prepared by dissolving 
povidone K30 in isopropyl alcohol. The wet masses were passed 
through a 12 mesh sieve and the wet granules produced was initially 
air-dried for 10 min and finally at 45-50 °C in a tray dryer for 2 h 
until the LOD (Loss on drying) of granules reached moisture limit 
between 2-3% w/w. The dried granules sieved by 16 mesh sieve 
were lubricated with magnesium stearate (which was sifted through 
60 mesh) and compressed to tablets. Formulations (F5-F7) were 
prepared using polyox WSR coagulant as retardant along with other 
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excipients. The ingredients passed through a 60-mesh sieve, mixed 
thoroughly in a rapid mixer granulator, lubricated and compressed. 
Before compression, the final blend was evaluated for its flow and 
compressibility characteristics. All the tablets compressed using 
Cadmach single punch tablet compression machine with 12 mm 
concave punch were stored in airtight containers for further study 
[15, 16]. The composition of the metformin hydrochloride sustained 
release layer is mentioned in table 1.  
Formulation of gliclazide layer (layer-2) 
Various formulations of gliclazide (G1-G9) were prepared with different 
ratios of Hydroxy Propyl Methyl Cellulose of different grades like HPMC-
K4M, HPMC-K15M, HPMC-K100M and other ingredients by taking 
appropriate quantities as mentioned in table 2. The granules were 
prepared by the wet granulation method. The ingredients passed 
through a 60-mesh sieve. A blend of all ingredients except glidant and 
lubricant mixed thoroughly in a rapid mixer granulator resulting in 
phase homogenization and granulated manually with a binder solution 
prepared by dissolving povidone K30 in isopropyl alcohol. The wet 
masses were passed through a 12 mesh sieve and the wet granules 
produced was initially air-dried for 10 min and finally at 45-50° in a tray 
dryer for 2 h until the LOD (Loss on drying) of granules reached 
moisture limit between 2-3% w/w. The dried granules sieved by a 16 
mesh sieve were lubricated with magnesium stearate (which was sifted 
through 60 mesh) and compressed to tablets. Before compression, the 
granules were evaluated for pre-compression parameters. The 
composition of the gliclazide layer is mentioned in table 2. 
Characterization of the powder blend  
Precompression parameters of the metformin hydrochloride and 
gliclazide powder blends such as angle of repose, bulk density, 
tapped density, Carr’s index, and Hausner’s ratio were determined 
for their micromeritic properties before compression of the tablet 
were mentioned in table 3 and 4 respectively. 
 
Table 1: Composition of metformin hydrochloride layer 
Ingredients (mg) Formulation code 
M1 M2 M3 M4 M5 M6 M7 
Metformin hydrochloride 500 500 500 500 500 500 500 
HPMC K100M 120 160 200 240 - - - 
PolyoxWSR coagulant - - - - 160 220 210 
MCC 140 100 60 20 - - - 
Mannitol - - - - 95 35 45 
PVP K 30 25 25 25 25 25 25 25 
IPA qs qs qs qs qs qs qs 
HPMC: Hydroxypropylmethylcellulose, MCC: Microcrystalline cellulose, PVP: Polyvinyl pyrrolidone, IPA: Isopropyl alcohol, qs: quantity sufficient. 
Total weight per tablet: 800 mg  
 
Table 2: Composition of gliclazide layer 
Ingredients (mg) Formulation code 
G1 G2 G3 G4 G5 G6 G7 G8 
Gliclazide 60 60 60 60 60 60 60 60 
DCP 90 70 50 90 80 70 90 80 
HPMC K4M 20 30 40 - - - - - 
HPMC K15M - -   20 30 40 - - 
HPMC K100M - - - - - - 20 30 
PVP K30 6 6 6 6 6 6 6 6 
Iron oxide yellow 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
SA 20 20 20 20 20 20 20 20 
IPA qs qs qs Qs qs qs qs qs 
Magnesium stearate 4 4 4 4 4 4 4 4 
DCP: Dicalcium phosphate, HPMC: Hydroxy Propyl Methyl Cellulose, PVP: Polyvinyl pyrrolidone, IPA: Isopropyl alcohol, SA: Sodium alginate, qs: 
quantity sufficient. Total weight per tablet: 200 mg 
 
Evaluation of marketed formulation exermet GZ 560 
The marketed product (Exermet GZ 560) was evaluated to determine 
thickness, weight and dissolution profile following the standard 
method of testing. The values of these properties are given in table 5. 
Evaluation of post-compression parameters 
Physicochemical properties of tablets 
The compressed monolithic matrix tablets are characterized for post-
compression properties like weight variation, friability, hardness and 
thickness as per IP and USP standard methods. The weight variation of 
the tablets was carried out with 20 tablets using an electronic balance 
(Shimadzu, Japan). Friability was determined using 10 tablets in a 
Roche friabilator (Pharma Lab, Ahmadabad, India) for 4 min at 25 
rpm. For each formulation, the hardness of 10 tablets was evaluated 
using a hardness tester (Monsanto hardness tester). The thickness of 
10 tablets was measured using Vernier Calipers [17, 18]. 
Drug content uniformity 
Twenty tablets weighed accurately and finely powdered. The 
powder equivalent to 500 mg of metformin hydrochloride and 60 
mg of gliclazide was transferred into a 100 ml volumetric flask. 50 
ml of pH 7.4 buffer was added to the powder and sonicated to 
dissolve completely. Then the volume made up to 100 ml with buffer 
and filtered by Whatman filter paper. 1 ml of filtered solution was 
withdrawn and diluted to 100 ml using the buffer. The Peak area of 
the sample solution was measured at 261 nm to calculate the 
concentration of the drug in the sample [19]. 
In vitro dissolution profiles  
The marketed and manufactured formulations were tested for in 
vitro drug release using USP Type II paddle dissolution apparatus 
(LAB INDIA 8000+). One matrix tablet was placed in each flask of the 
dissolution apparatus and dissolution was conducted for 24 h at 50 
rpm at 37±0.5 °C. Initially, the study was performed in 900 ml of 0.1 
N HCI for 2 h followed by 900 ml of pH 7.4 phosphate buffer 5 ml of 
sample was withdrawn at time intervals 2, 4, 6, 8, 10, 12, 16 and 24 
h and the same volume was replaced to maintain sink conditions 
[20-21]. During sampling, samples were filtered through Whatman 
filter paper, suitably filtered and analyzed by the reported HPLC 
method at 261 nm using standard stocks. Each sample was injected 
six times and the sample retention times were observed in all cases. 
Retention time about 3.27 min for metformin hydrochloride and 
6.12 min for gliclazide observed for stock solution. 
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Dissolution data analysis 
The dissolution profile comparison carried out using the model-
independent or model-dependent method. A simple model-
independent approach uses a difference factor (f1) and a similarity 
factor (f2) to compare dissolution profiles. 
f1 = {[Σ t=1n |Rt-Tt|]/[Σ t=1nRt]} ×100 
f2 = 50 x log {[1+(1/n) ∑ t = 1n(Rt–Tt) 2]- °.5x 100} 
Where, Rt and Tt represent the average percent dissolved at time t 
for reference and test, respectively and n is the number of time 
points tested.  
Dissolution profile considered satisfactory if f1 values lie below 50 
(nearing zero) and f2 values lie more than 50 (nearing 100). If the f2 
value is between 50-100, the value of the test and the reference are 
identical. The model-independent method is most suitable for 
dissolution profile comparison when three to four or more 
dissolution time points are available [23]. 
Kinetic model fitting 
Dissolution data of the above two methods were fitted in Zero 
order, First order and Higuchi equations. Based on the slope and 
r2 values obtained, the mechanism of drug release was 
determined. 
Accelerated stability studies 
The accelerated stability testing was conducted to provide evidence 
on how the quality of a drug substance varies with time under 
influence of a variety of environmental factors such as temperature, 
humidity, light and enables recommended storage conditions. The 
study was conducted by wrapping the bilayer tablets in aluminum 
foils and kept at 25 °C/60% RH and 40 °C/75% RH. Then the tablets 
were checked for appearance, thickness, and hardness. In addition, 
drug content and dissolution studies were performed periodically 
for 6 mo and compared with initials as per ICH guidelines [26]. 
RESULTS AND DISCUSSION 
Drug-excipient interaction study 
The compatibility of the pure drug with its excipients on physical 
observation exhibited no interaction; therefore, the excipients were 
selected for formulation. The distinctive melting points were 
observed for metformin hydrochloride at 224 °C and gliclazide at 
182 °C and no evident melting point changes were noted indicating 
overall compatibility. 
FT-IR spectroscopy 
The FT-IR spectrum of metformin hydrochloride and gliclazide in 
formulations was as shown in fig. 3C. FT-IR studies revealed that 
metformin hydrochloride showed two typical bands at 3371 and 
3296/cm due to N-H primary stretching vibrations and a band at 
3174/cm due to N-H secondary stretching, and characteristics bands 
at 624 and 1584/cm assigned to C=N stretching. No significant shifts 
of reduction in the intensity of the FT-IR bands of metformin 
hydrochloride were observed which indicates the absence of drug-
drug interaction and drug-polymer interaction between metformin 
hydrochloride and Polyox WSR coagulant.  
Hence, these two drugs were selected for the development of 
sustained-release bilayer tablets and polyox WSR coagulant was 
selected as a release-retarding agent. An IR spectrum of pure 
gliclazide shows two characteristic peaks. A peak at 3414.85 cm-1 
due to NH group and another peak at 1636.79 cm-1 due to C=O as 
observed in fig. 3B showing no interaction indicating overall 
compatibility with the polymer HPMC K100M and excipients. 
Characterization of powder blend 
The results of the pre compressional parameters such as bulk density, 
tapped density angle of repose, Hausner’s ratio and compressibility 
index of all batches of SR blend containing metformin hydrochloride 
and gliclazide exhibited good characteristics. All the formulations 
showed good compressibility and flow properties than pure drugs. 
The precompression values of metformin hydrochloride and gliclazide 
blend were indicated in table 3 and table 4 respectively. 
 
 
Fig. 3: Fourier transform infrared spectrum (A) Metformin hydrochloride (B) Gliclazide (C) Metformin hydrochloride+Gliclazide (D) 
Metformin hydrochloride+Polyox WSR coagulant (E) Gliclazide+HPMC K 100M 
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Table 3: Precompression parameters of metformin hydrochloride formulation M1–M7 
Formulation code Bulk density (g/cm3) Tapped density (g/cm3) Compressibility (%) Hausner’s ratio Angle of repose ( °) 
M1 0.62±0.009 0.71±0.038 12.8 1.14 23 
M2 0.72±0.012 0.85±0.0983 15.8 1.18 25 
M3 0.68±0.018 0.78±0.027 13 1.14 25 
M4 0.62±0.06 0.74±0.012 16.5 1.19 22 
M5 0.61±0.053 0.79±0.042 22.2 1.28 28 
M6 0.62±0.038 0.72±0.082 13.7 1.15 20 
M7 0.66±0.039 0.72±0.013 9.14 1.1 18 
mean±SD, n = 3 SD=Standard deviation 
 
Table 4: Pre compression parameters of gliclazide formulation G1–G8 
Formulation code Bulk density (g/cm3) Tapped density (g/cm3) Compressibility (%) Hausner’s ratio Angle of repose ( °) 
G1 0.65±0.072 0.79±0.082 17.6 1.21 20.6 
G2 0.54±0.012 0.69±0.032 22 1.28 21.7 
G3 0.57±0.019 0.71±0.015 19.6 1.24 19.7 
G4 0.52±0.062 0.68±0.082 22.4 1.29 19.3 
G5 0.53±0.083 0.68±0.029 22.5 1.29 22.6 
G6 0.54±0.022 0.65±0.072 16.3 1.29 20.1 
G7 0.56±0.014 0.69±0.012 19.8 1.24 18.7 
G8 0.52±0.092 0.68±0.062 22.4 1.29 19.8 
mean±SD, n = 3 
 
Table 5: Physical evaluation of the innovator 
Brand name Exermet GZ 560 
Manufacturer Cipla 
Composition Metformin hydrochloride–500 mg 
Gliclazide–60 mg 
Total weight of the tablet 1000 mg 
Thickness 5.3 mm 
Drug content Metformin hydrochloride–99.97±0.11% 
Gliclazide 99.96±0.41 % 
 
Evaluation of post-compression parameters of tablets 
All tablets appeared smooth and oblong. The weight of the 
metformin hydrochloride layer was kept constant to 800 mg. All 
tablet batches qualify the tablet weight variation test and found 
variation 100±5 % within range; friability below 1%; drug content 
90-110% within limit and deviation in thickness found less than 5%. 
Results of post-compression parameters of metformin hydrochloride 
tablets were observed in table 6. The optimized metformin 
hydrochloride formulation was further used to prepare bilayer tablets 
using different gliclazide formulations. Results of post-compression 
parameters of bilayer tablets were observed in table 7. 
 
Table 6: Post compression parameters of metformin hydrochloride formulations M1–M7 
Formulation code Weight variation (mg) Hardness (Kg/Cm2) Thickness (mm) Friability (%) Content uniformity % (layer  1) 
M1 800±0.19 7.5±0.23 5.1±0.21 0.41±0.002 99.28±0.57 
M2 800±0.38 7.8±0.24 5.02±0.15 0.68±0.005 99.57±0.86 
M3 800±0.79 8.5±0.23 5.04±0.23 0.53±0.005 99.75±0.36 
M4 800±0.74 8.9±0.26 5.08±0.42 0.36±0.008 99.78±0.87 
M5 800±0.56 8.3±0.93 5.11±0.33 0.86±0.002 98.68±0.28 
M6 800±0.49 8.5±0.27 5.04±0.13 0.72±0.004 99.83±0.39 
M7 800±0.68 8.4±0.23 5.03±0.26 0.93±0.007 99.95±0.26 
mean±SD, n = 3 
 
Table 7: Post compression parameters of gliclazide formulation G1-G8 
Formulation code Weight variation (mg) Hardness (Kg/ Cm2) Thickness (mm) Fr iability (% ) Content uniformity (% ) (Layer  2) 
G1 200±0.67 7.5±0.23 2.11±0.03 0.54±0.0098 98.5±0.83 
G2 200±0.29 6.7±0.28 2.01±0.83 0.67±0.0021 99.4±0.75 
G3 200±0.57 7.4±0.83 2.13±0.12 0.49±0.0024 99.3±0.62 
G4 200±0.75 8.5±0.26 2.17±0.08 0.81±0.0027 99.7±0.69 
G5 200±0.38 8.5±0.73 2.04±0.42 0.32±0.0037 99.5±0.62 
G6 200±0.32 8.8±0.27 2.08±0.16 0.65±0.0073 98.6±1.04 
G7 200±0.61 8.5±0.74 2.04±0.28 0.87±0.0028 98.6±1.67 
G8 200±0.85 8.6±0.51 2.03±0.34 0.62±0.0065 99.7±0.19 
mean±SD, n = 3 
A. Rajeswari et al. 
Int J App Pharm, Vol 13, Issue 5, 2021, 343-350 
348 
In vitro dissolution studies of the sustained-release layer 
containing metformin hydrochloride 
All the formulations subjected to in vitro dissolution studies 
revealed that tablets containing release modifiers exhibited 
sustained release of metformin hydrochloride and gliclazide. The 
dissolution profile of formulations containing metformin 
hydrochloride was represented in fig. 4. The dissolution profile of 
metformin hydrochloride formulation revealed that M1-M3 
formulations released the drug completely by the end of 12 h, which 
is probably due to faster dissolution of the highly water-soluble drug 
from the core and its diffusion out of the matrix forming the pores 
for the entry of solvent molecules. A suitable sustained-release 
formulation should release the required amount of drug in the initial 
hour, followed by slow release. Formulation M4 (30% HPMC K100M) 
exhibited the slowest dissolution profile which was consistent with 
USP specification. In contrast, the release of metformin hydrochloride 
from formulation M5-M7 prepared using polyox WSR coagulant was 
extended up to 24 h. Batch M7 prepared by direct compression 
method using polyox WSR coagulant (25%) exhibited a good drug 
release profile. Data of comparison of formulations M4 and M7 with 
innovator by similarity and dissimilarity factor represented in table 8 
reveals that M7 is the promising batch and selected as the best 
formulation for further studies. 
 
Table 8: Comparision of formulations with innovator by similarity and dissimilarity factor 
Formulation f2 value f1 value 
M4 72.05 3.6 
M7 79.95 2.36 
 
 
Fig. 4: In vitro dissolution profile of Metformin hydrochloride formulation M1-M7 and innovator 
 
Sustained-release layer containing gliclazide 
The dissolution profile of gliclazide formulations was represented in 
fig. 5. Formulation G3 and G6 displayed a cumulative release of 
nearly 98.7% and 99.6% in 12 h and 16h respectively where 40% of 
polymers HPMC K4M and K15M were employed. In contrast, the 
formulation G8 exhibited a better-controlled release profile of 
99.8% at 24 h as represented in fig. 5. 
  
 
Fig. 5: In vitro dissolution profile of gliclazide formulation G1-G8 and Innovator 
 
Here, the polymer HPMC K100M showed a better rate of retardant 
ability than the above two variants at a lesser concentration. The 
hydration rate of HPMC increases with an increase in the Hydroxyl 
Propyl content and the solubility of HPMC is pH-independent [22]. 
The water-repelling property of higher variants of HPMC retarded 
the drug release from the matrix by preventing the penetration of 
solvent molecules. HPMC K100M was judiciously selected in 
preparation due to its profound ability to form a strong viscous gel 
on contact with aqueous media, which helps in controlling the 
delivery of highly water-soluble drugs [24].  
Final compression of bilayer tablets 
Based on results of in vitro dissolution studies batch M7 of 
metformin hydrochloride and batch G8 of gliclazide were selected to 
prepare bilayer tablets. Initially, the metformin hydrochloride blend 
was poured into the die cavity and compressed with moderate force. 
Then the upper punch was lifted and the gliclazide granules were 
poured in the die cavity, containing initially compressed layer 1 and 
compressed with full force to form a bilayer tablet of 1000 mg with a 
hardness of 7-8 Kg/Cm2 using Cadmach single punch compression 
machine with 12 mm concave punch and die [26]. The dissolution 
profiles of the individual layer in the final formulation were 
compared with the innovator (Exermet GZ 560) and results were 
represented in fig. 6. From the graphs, it is evident bilayer tablet 
shows a similar release pattern as Exermet GZ 560 with a good 
similarity factor 79.95 and 73.62 for metformin hydrochloride and 
gliclazide respectively. The post-compression parameters of the 
bilayer tablets were found to be within the limits. 
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Fig. 6: Comparison of dissolution profiles of (a) Metformin hydrochloride in formulation M7 and Innovator. (b) Gliclazide in formulation 
G8 and innovator 
 
 
Fig. 7: Zero-order plot of drug release in an optimized bilayer tablet 
 
 
Fig. 8: First Order plot of drug release in an optimized bilayer tablet 
 
Drug release kinetics 
The release mechanism of metformin hydrochloride and gliclazide 
from bilayered optimized formulation was studied by fitting the data 
obtained from in vitro release studies into zero-order, first-order, 
Higuchi and Korsmeyer-Peppas models. 
It is evident from fig. 8 that a linear relationship was obtained with 
‘r’ value close to unity and higher than ‘r’ obtained from the zero-
order equation for optimized bilayer formulation of metformin 
hydrochloride and gliclazide, showing that the release is an apparent 
first-order process. This indicates that the amount of drug released 
is dependent on the matrix drug load. 
 
 
Fig. 9: Higuchi plot of optimized bilayer tablet 
 
The linearity of the Higuchi plot indicates that the release process of 
metformin hydrochloride and gliclazide from the optimized 
formulation is diffusion controlled. The Slope values in the 
Korsmeyer-Peppas equation in fig. 10 indicate that the diffusion 
mechanism involved was Fickian in the case of metformin 
hydrochloride and the Non-fickian in the case of Gliclazide in the 
final bilayer tablet. Thus, the sustained-release bilayer tablet 
formulation displayed the release of the required quantity of drug 
with predetermined kinetics to maintain an effective drug plasma 
concentration.
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Fig. 10: Korsmeyer-peppas plot of optimized bilayer tablet 
 
Stability studies 
Stability studies of sustained-release bilayer tablets developed in 
this investigation were carried out for 6 mo in specified conditions. 
The results reveal that there was no significant change in physical 
characteristics, % drug content and % drug release in 24 h. when 
stored at 40±2 °C/75±5% RH. Therefore, it has been considered that 
formulation having good stability. 
CONCLUSION 
The monolith diffusion-controlled bilayer tablets of metformin 
hydrochloride and gliclazide were successfully developed using the 
lesser concentration of polyox WSR coagulant and HPMC K 100M as 
retardant polymers respectively. In vitro release profiles revealed that 
99.93% of the metformin hydrochloride and 99.65% gliclazide were 
released from the final optimized formulation at the end of 24 h. The 
drug release follows first order and is diffusion controlled. Therefore, the 
designed formulation offers improved patient compliance and 
convenience with better postprandial hyperglycemic control with once-
a-day dosing. The sustained release of the drug up to 24 h regulates 
antidiabetic activity round the clock with minimal side effects. 
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